Revium Rx. 8-K

What Happened
Revium Rx (RVRC) filed an 8-K announcing that Inna Martin resigned as a member of the company's Board of Directors and from her roles as Chief Operating Officer and President, effective June 16, 2026. The company and its subsidiary, Revium Rx Ltd., executed a Separation Agreement effective the same date. Under that agreement, Ms. Martin’s employment and consultancy engagement with Revium Ltd. will terminate on September 10, 2026. The exercise period for her vested stock options to purchase up to 2,440,000 shares of Revium common stock has been extended to September 30, 2028, and her shares and options remain subject to sale restrictions in the Separation Agreement.

Key Details

• Resignation effective: June 16, 2026 (board membership and COO/President roles).
• Separation Agreement effective: June 16, 2026; employment/consulting ends: September 10, 2026.
• Vested stock options affected: options to buy up to 2,440,000 shares; exercise period extended to September 30, 2028.
• Ms. Martin held no board committee positions at the time of her resignation; shares/options subject to sale restrictions.

Why It Matters
This is a material executive change: Revium is losing its COO and President, which could affect day-to-day operations and strategic execution until a successor is named. The Separation Agreement and extended option exercise window clarify Ms. Martin’s post-departure economic rights (longer time to exercise vested options) while imposing sale restrictions that may limit near-term share sales. Investors should note the leadership change and monitor subsequent filings for any appointment of a replacement or additional details on management transition.